- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 405/12
Total number of patents in this class: 8350
10-year publication summary
|
575
|
523
|
554
|
531
|
532
|
488
|
487
|
561
|
486
|
409
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vertex Pharmaceuticals Incorporated | 1621 |
171 |
| Bristol-myers Squibb Company | 4824 |
127 |
| Epizyme, Inc. | 375 |
114 |
| Boehringer Ingelheim International GmbH | 4637 |
112 |
| Takeda Pharmaceutical Company Limited | 2716 |
90 |
| F. Hoffmann-La Roche AG | 7934 |
86 |
| Novartis AG | 10626 |
85 |
| Merck Patent GmbH | 5755 |
78 |
| Merck Sharp & Dohme LLC | 3732 |
75 |
| Janssen Pharmaceutica N.V. | 3350 |
69 |
| AstraZeneca AB | 2851 |
67 |
| Bayer Cropscience AG | 1991 |
66 |
| The Regents of the University of California | 20268 |
61 |
| Idemitsu Kosan Co., Ltd. | 4225 |
60 |
| Bayer AG | 3388 |
58 |
| LG Chem, Ltd. | 17682 |
49 |
| Samsung Display Co., Ltd. | 36165 |
48 |
| Pfizer Inc. | 3404 |
47 |
| Abbvie Inc. | 1814 |
47 |
| Allergan, Inc. | 2315 |
44 |
| Other owners | 6796 |